Prope tolerance - The future of organ transplantation from the laboratory to the clinic

Transplant Immunology

Volumn 13, Issue 2, 2004, Pages 83-86

  Calne, R Y ^a  

^a CB2 2AH ^*  (United Kingdom)

Author keywords

Clinic; Laboratory; Organ transplantation

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALEMTUZUMAB; ANTILEUKEMIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DIPHTHERIA TOXOID; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISOLONE; RAPAMYCIN;

ACUTE GRAFT REJECTION; ALLOGRAFT; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW TRANSPLANTATION; BRAIN TUMOR; CALCINOSIS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG BLOOD LEVEL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MICROCHIMERISM; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SEPSIS; SHORT SURVEY; SIDE EFFECT; TRANSPLANTATION TOLERANCE; TUBERCULOSIS;

EID: 4544246589     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2004.05.008     Document Type: Article

References (33)

1. Murray J.E., Merrill J.P., Harrison J.H. Renal homotransplantation in identical twins. Surg. Forum. 1955;432-436
2. Gibson T., Medawar P.B. The fate of skin homografts in man. J. Anat. 77:1943;299-310
3. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature. 172:1953;603-606
4. Thomas E.D., Lochte H.L. Jr., Cannon J.H., et al. Supralethal whole body irradiation and isologous marrow transplantation in man. J. Clin. Invest. 38:1959;1709-1716
5. Sayegh M.H., Fine N.A., Smith J.L., Rennke H.G., Milford E.L., Tilney N.L. Immunologic tolerance to renal allografts after bone marrow transplants. Ann. Intern. Med. 114:1991;954-955
6. Helg C., Chapuis B., Bolle J.F., Morel P., Salomon D., Roux E., et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation. 58:1994;1420-1422
7. Jacobsen N., Taaning E., Ladefoged J., Kristensen J.K., Pedersen F.K. Tolerance to an HLA-B, DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet. 343:1994;800
8. Calne R.Y. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant. Bull. 28:1961;445-461
9. Murray J.E., Merrill J.P., Harrison J.H., et al. Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N. Engl. J. Med. 268:1963;1315-1323
10. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497
11. Borel J.F., Feurer C., Gubler H.U., Stahelin H. Biological effects of cyclosporine A: a new antilymphocytic agent. Agents Actions. 6:1976;468-475
12. Calne R.Y., White D.J.G., Thiru S., Evans D.B., McMaster P., Dunn D.C., et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 2:1978;1323-1327
13. Nagano H., Tilney N.L. Chronic allograft failure: the clinical problem. Am. J. Med. Sci. 313:1997;305-309
14. Cecka J.M. The UNOS scientific renal transplant registry: ten years of kidney transplants. Cecka J.M., Terasaki Pl. Clinical transplants. 1997;1-15 UCLA Tissue Typing Laboratory, Los Angeles (CA)
15. Beveridge T., Calne R.Y. for the European multicentre trial group Cyclosporine (Sandimmun) in cadaveric renal transplantation. Transplantation. 59:1995;1568-1570
16. Calne R.Y., Sells R.A., Pena J.R., Davis D.R., Millard P.R., Herbertson B.M., et al. Induction of immunological tolerance by porcine liver allografts. Nature. 223:1969;472-476
17. Mazariegos G.V., Reyes J., Marino I., et al. Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant. Proc. 29:1997;1174-1177
18. Woodruff M.F., Nolan B., Anderton J.L., Abouna G.M., Morton J.B., Jenkins A.M. Long survival after renal transplantation in man. Br. J. Surg. 63:1976;85-101
19. Campos H., Kreis H.A., Rioux P., Crosnier J. Azathioprine withdrawal in renal transplant recepients. A long-term follow-up. Transplantation. 38:1984;29-31
20. Calne R.Y., Watson C.J.E., Brons I.G.M., Makisalo H., Metcalfe S.N., Sritwatanawongsa V., et al. Tolerance of porcine renal allografts induced by donor spleen cells and seven days' treatment with cyclosporin. Transplantation. 57:1994;1433
21. Thomas F.T., Contreras J.L., Smyth C.A., Lobashevsky A., Jenkins S., Hubbard W.J., et al. Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of Type 1 diabetes. Diabetes. 50:2001;1227-1236
22. Knechtle S., Vargo D., Fechner J., et al. FN-18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation. 63:1997;1-6
23. Contreras J.L., Jenkins S., Eckhoff D.E., Hubbard W.J., Lobashevsky A., Bilbao G., et al. Stable α- and β-islet cell function after tolerance induction to pancreatic islet allografts in diabetic primates. Am. J. Transplant. 3:2003;128-138
24. Thomas F.T., Ricordi C., Contreras J.L., Hubbard W.J., Ling Jiang X., Eckhoff D.E. Reversal of naturally occurring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation. 67:1999;846-854
25. Kirk A.D., Harlan D.M., Armstrong N.N., et al. CTL 4-Ig and antiCD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U. S. A. 94:1997;8789-8794
26. Hale G., Dyer M.J., Clark M.R., Phillips J.M., Marcus R., Riechmann L., et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody of Campath 1H. Lancet. 2:1998;1394-1399
27. Friend P.J., Rebello P., Oliveira D., Manna V., Cobbold S.P., Hale G., et al. Successful treatment of renal allograft rejection with a humanised antilymphocyte monoclonal antibody. Transplant. Proc. 27:1995;869
28. Calne R.Y., Friend P.J., Moffatt S., Bradley A., Hale G., Firth J., et al. Prope tolerance, perioperative Campath 1H and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 351:1998;1701-1702
29. Calne R.Y., Moffatt S.D., Friend P.J., Jamieson N.V., Bradley J.A., Hale G., et al. Campath 1H allows low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 68:1999;1613-1616
30. Calne R.Y. Progress towards tolerance and xenografting. Trans. Proc. 29 World Transplantation, Barcelona. 1997;16-18 Elsevier Science Inc., New York
31. Starzl T.E., Murase N., Abu-Eimagd K., Gray E.A., et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 361:2003 (May 3);1502-1510
32. Buhler L.H., Spitzer T.R., Sykes M., et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 74:2002;1405-1409
33. Thomas J.M., Eckhoff D.E., Contreras J.L., et al. Durable donor-specific T and B cell tolerance in Rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin. Transplantation. 69:2000;2497-2503